GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huakang Biomedical Holdings Co Ltd (HKSE:08622) » Definitions » Tax Expense

Huakang Biomedical Holdings Co (HKSE:08622) Tax Expense : HK$0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Huakang Biomedical Holdings Co Tax Expense?

Huakang Biomedical Holdings Co's tax expense for the months ended in Jun. 2024 was HK$0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.00 Mil.


Huakang Biomedical Holdings Co Tax Expense Historical Data

The historical data trend for Huakang Biomedical Holdings Co's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huakang Biomedical Holdings Co Tax Expense Chart

Huakang Biomedical Holdings Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only 1.05 0.30 0.39 0.08 -

Huakang Biomedical Holdings Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 - -0.06 - -

Huakang Biomedical Holdings Co Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huakang Biomedical Holdings Co  (HKSE:08622) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Huakang Biomedical Holdings Co Tax Expense Related Terms

Thank you for viewing the detailed overview of Huakang Biomedical Holdings Co's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Huakang Biomedical Holdings Co Business Description

Traded in Other Exchanges
N/A
Address
No.16 Yinkui Road, 1-3 floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN
Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.
Executives
Arena Investment Management (singapore) Pte Ltd 2102 Investment manager
Arena Investors, Lp 2102 Investment manager
Arena Sg Spv I, Llc 2201 Interest of corporation controlled by you
Tgga, Llc 2106 Person having a security interest in shares
Lau Lai Yee 2201 Interest of corporation controlled by you
Kokusai Resources Company Limited 2101 Beneficial owner
Zhang Shuguang 2101 Beneficial owner
Crystal Grant Limited 2101 Beneficial owner
Chang Yim Yang 2401 A concert party to an agreement to buy shares
Ever Charming Inc. 2101 Beneficial owner
Wealthy Pride Investment Limited 2101 Beneficial owner

Huakang Biomedical Holdings Co Headlines

No Headlines